Hansoo Michael Keyoung - 16 Sep 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
Director
Signature
/s/ Hansoo Michael Keyoung
Issuer symbol
KAPA
Transactions as of
16 Sep 2025
Net transactions value
$0
Form type
4
Filing time
26 Nov 2025, 17:27:13 UTC
Previous filing
24 Sep 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Keyoung Hansoo Michael Director C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES /s/ Hansoo Michael Keyoung 26 Nov 2025 0001824764

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +10,000 $0.000000 10,000 16 Sep 2025 Direct F1, F2
transaction KAPA COMMON STOCK Award $0 +19,084 +191% $0.000000 29,084 08 Oct 2025 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO.
F2 Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.
F3 Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F4 Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting.